Development of Novel Indolyl-derived Biologically Active Compounds
von El Sayed, Mardia
inklusive MwSt. - GRATIS LIEFERUNG
Dir gefällt dieses Produkt? Sag's weiter!
CHF 87.20 inkl. USt.
Nur noch 1 Stück verfügbar Nur noch 1 Stück verfügbar Mehr als 10 Stück verfügbar
MRSA is a methicillin-resistance Staphylococcus aureus and a strain of Staphylococcus aureus that developed resistance to the killing effect of the beta-lactam antibiotics, which include the penicillins (methicillin, dicloxacillin, oxacillin, etc.), MRSA is sometimes called a "superbug" because it is very difficult to treat and it causes a huge number of infections every year in hospitals all over the world. The novel synthesized indoles will add a valuable new addition to the antibacterial arsenal for MRSA infections, it would be new bactericidal agents effective against resistant isolates or standard. We have shown for the first time that the cycloalkanoindoles,bis-indolobenzocarbazoles and the oxidized bis-indolylmethenes inhibited growth of drug resistant MRSA either standard or isolate and other Gram-positive bacteria at low concentrations. Some of these novel bis- and tris-indolyl compounds described in this work have been screened in the national cancer institute (NCI) in USA for one and five dose that showed the highest antipoliferative activity in a nanomolar scale towards the selected cancers cell lines (Non small lung: NCIeH460, Ovarian: OVCAR-4 and Breast: MCF).
El Sayed, Mardia
Author is Dr/Mardia Telep El Sayed, Egyptian researcher at National Research Centre, Applied Organic Chemistry Department. In 2009 she started her PhD scholarship in Synthetic Organic Chemistry/ Martin Luthr University Halle/ Germany and recieved her PhD in April 2013. She has BSc and MSc in Organic Chemistry from Egyptian Universties.
LAP Lambert Academic Publishing
0.22 x 0.15 x 0.018 m; 0.513 kg